Posted by Michael Wonder on 23 Jan 2023
Blueprint Medicines announces FDA acceptance of supplemental new drug application for Ayvakit (avapritinib) for the treatment of indolent systemic mastocytosis
23 January 2023 - FDA grants priority review and sets PDUFA action date of 22 May 2023.
Blueprint Medicines today announced that the US FDA has accepted the company's supplemental new drug application for Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis.
